Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
暂无分享,去创建一个
John T. Wei | M. Rubin | A. Chinnaiyan | J. R. Prensner | M. A. Rubin | J. T. Wei | A. M. Chinnaiyan | John R. Prensner
[1] Graham A. Colditz,et al. Applying What We Know to Accelerate Cancer Prevention , 2012, Science Translational Medicine.
[2] J. Carpten,et al. Germline mutations in HOXB13 and prostate-cancer risk. , 2012, The New England journal of medicine.
[3] L. Tanoue,et al. Reduced lung cancer mortality with low-dose computed tomographic screening , 2011 .
[4] Christina Bougatsos,et al. Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.
[5] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[6] Jean-Pierre Gillet,et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance , 2011, Proceedings of the National Academy of Sciences.
[7] D. Kerr,et al. Predictive biomarkers: a paradigm shift towards personalized cancer medicine , 2011, Nature Reviews Clinical Oncology.
[8] C. Gatsonis,et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .
[9] Nallasivam Palanisamy,et al. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.
[10] John T. Wei,et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression , 2011, Nature Biotechnology.
[11] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[12] Wei Yan,et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.
[13] Sarat Chandarlapaty,et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.
[14] U. Landegren,et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer , 2011, Proceedings of the National Academy of Sciences.
[15] Dan Stoianovici,et al. Advancements in MR imaging of the prostate: from diagnosis to interventions. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.
[16] Guido Jenster,et al. Exosomes as biomarker treasure chests for prostate cancer. , 2011, European urology.
[17] D. Ransohoff,et al. Biomarker studies: a call for a comprehensive biomarker study registry , 2011, Nature Reviews Clinical Oncology.
[18] Yousef Mazaheri,et al. MRI of the prostate: Clinical relevance and emerging applications , 2011, Journal of magnetic resonance imaging : JMRI.
[19] Chunsheng Han,et al. The Prostate 71 : 209 ^ 224 ( 2011 ) Meta-Analysis ofGenome-Wide andReplication Association Studies on ProstateCancer , 2010 .
[20] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[21] M. Kattan,et al. Development and validation of a nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session in the era of extended prostate sampling , 2010, BJU international.
[22] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[23] L. Santarpia,et al. Breast cancer assessment tools and optimizing adjuvant therapy , 2010, Nature Reviews Clinical Oncology.
[24] E. Diamandis,et al. Cancer biomarkers: can we turn recent failures into success? , 2010, Journal of the National Cancer Institute.
[25] C. Oeser,et al. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. , 2010, Health technology assessment.
[26] R. V. D. van den Bergh,et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. , 2010, European urology.
[27] Jaya M Satagopan,et al. TMPRSS2–ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features , 2010, Modern Pathology.
[28] J C Wyatt,et al. Computerised decision support systems in order communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems. , 2010, Health technology assessment.
[29] H. Welch,et al. Overdiagnosis in cancer. , 2010, Journal of the National Cancer Institute.
[30] Milton C Weinstein,et al. Comparative effectiveness and health care spending--implications for reform. , 2010, The New England journal of medicine.
[31] A. D'Amico,et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.
[32] Francisco M. De La Vega,et al. Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing , 2010, Science Translational Medicine.
[33] Boris Freidlin,et al. Randomized clinical trials with biomarkers: design issues. , 2010, Journal of the National Cancer Institute.
[34] F. Song,et al. Dissemination and publication of research findings: an updated review of related biases. , 2010, Health technology assessment.
[35] T. H. van der Kwast,et al. False-negative Prostate Needle Biopsies: Frequency, Histopathologic Features, and Follow-up , 2010, The American journal of surgical pathology.
[36] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[37] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[38] Laura Esserman,et al. Rethinking screening for breast cancer and prostate cancer. , 2009, JAMA.
[39] M. Stockler,et al. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. , 2009, Cancer research.
[40] John T. Wei,et al. Rational approach to implementation of prostate cancer antigen 3 into clinical care , 2009, Cancer.
[41] A. D'Amico,et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. , 2009, JAMA.
[42] F. Saad,et al. PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.
[43] R. Shah,et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression , 2009, Modern Pathology.
[44] J. Schalken,et al. The use of PCA3 in the diagnosis of prostate cancer , 2009, Nature Reviews Urology.
[45] X. Breakefield,et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer , 2009, British Journal of Cancer.
[46] D. Dearnaley,et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.
[47] Angela Mariotto,et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.
[48] Lori J Sokoll,et al. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. , 2009, The Journal of urology.
[49] W. Gerald,et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.
[50] Pamela A Shaw,et al. Methods for Assessing Improvement in Specificity When a Biomarker is Combined With a Standard Screening Test , 2009, Statistics in biopharmaceutical research.
[51] A. Chinnaiyan,et al. Oncogenic gene fusions in epithelial carcinomas. , 2009, Current opinion in genetics & development.
[52] Michel Bolla,et al. [EAU guidelines on prostate cancer]. , 2009, Actas urologicas espanolas.
[53] H. Carter,et al. Words of wisdom. Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. , 2009, European urology.
[54] P. Schellhammer. Words of wisdom. Re: Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. , 2009, European urology.
[55] John T. Wei,et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.
[56] Monique J. Roobol,et al. Mortality Results from a Randomized ProstateCancer Screening Trial , 2009 .
[57] O. Ludkovski,et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.
[58] Rebecca O Barnes,et al. Influence of Evolution in Tumor Biobanking on the Interpretation of Translational Research , 2008, Cancer Epidemiology Biomarkers & Prevention.
[59] E. Diamandis,et al. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. , 2008, Clinical chemistry.
[60] Mesut Remzi,et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. , 2008, European urology.
[61] Holly Janes,et al. Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.
[62] K. Pienta,et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.
[63] I. Thompson,et al. Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention , 2008, Cancer Prevention Research.
[64] Wadih Arap,et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.
[65] C. Stephan,et al. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. , 2008, Journal of proteome research.
[66] C. Sawyers. The cancer biomarker problem , 2008, Nature.
[67] Andrew J. Vickers,et al. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.
[68] H Ballentine Carter,et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. , 2008, European urology.
[69] Pär Stattin,et al. Cumulative association of five genetic variants with prostate cancer. , 2008, The New England journal of medicine.
[70] P. Scardino,et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] Jianjun Yu,et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. , 2008, Cancer research.
[72] J Cuzick,et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.
[73] B. Trock,et al. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. , 2008, The Journal of urology.
[74] David F Ransohoff,et al. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. , 2007, Journal of clinical epidemiology.
[75] Glenn Heller,et al. Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.
[76] J. Witjes,et al. Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer , 2007, Clinical Cancer Research.
[77] P. Walsh. The discovery of the cavernous nerves and development of nerve sparing radical retropubic prostatectomy. , 2007, The Journal of urology.
[78] W. Catalona,et al. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. , 2007, The Journal of urology.
[79] R. Millikan,et al. Prostate cancer progression in the presence of undetectable or low serum prostate‐specific antigen level , 2007, Cancer.
[80] P. Humphrey,et al. Diagnosis of adenocarcinoma in prostate needle biopsy tissue , 2007, Journal of Clinical Pathology.
[81] P. Kantoff,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.
[82] L. Ferrucci,et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. , 2006, Journal of the National Cancer Institute.
[83] Steven A Carr,et al. Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.
[84] D. Bates,et al. The impact of a suspicious prostate biopsy on patients’ psychological, socio-behavioral, and medical care outcomes , 2006, Journal of General Internal Medicine.
[85] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[86] John P A Ioannidis,et al. Selective reporting biases in cancer prognostic factor studies. , 2005, Journal of the National Cancer Institute.
[87] Debashis Ghosh,et al. Decreased α-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death , 2005, Cancer Epidemiology Biomarkers & Prevention.
[88] P. Walsh,et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2005, The Journal of urology.
[89] M Bolla,et al. EAU guidelines on prostate cancer. , 2001, European urology.
[90] S. Cadrin,et al. A Preliminary Analysis , 2005 .
[91] Ming-Hui Chen,et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2004, The New England journal of medicine.
[92] Georg Bartsch,et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. , 2004, The Journal of urology.
[93] J. Crowley,et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.
[94] G. Yousef,et al. An update on human and mouse glandular kallikreins. , 2004, Clinical biochemistry.
[95] K. Pettersson,et al. Prostate-Specific Antigen in Serum Occurs Predominantly in Complex with a . 1-Antichymotrypsin , 2004 .
[96] T. Stamey,et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. , 2003, The Journal of urology.
[97] Zhong Jiang,et al. Expression of α-methylacyl-coa racemase (p504s) in various malignant neoplasms and normal tissues: a study of 761 cases , 2003 .
[98] H. Klocker,et al. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. , 2003, Urology.
[99] G. Bubley,et al. Biology of prostate-specific antigen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] N. Anderson,et al. The Human Plasma Proteome: History, Character, and Diagnostic Prospects , 2003, Molecular & Cellular Proteomics.
[101] G. Bubley,et al. BIOLOGY OF PROSTATESPECIFIC ANTIGEN , 2003 .
[102] Evert-Ben van Veen,et al. Tumour banks: well-guarded treasures in the interest of patients , 2003, Nature Reviews Cancer.
[103] L. Kiemeney,et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.
[104] Debashis Ghosh,et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. , 2002, JAMA.
[105] N. Anderson,et al. HISTORY, CHARACTER, AND DIAGNOSTIC PROSPECTS* , 2002 .
[106] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[107] M. Lukeš,et al. Prostate-specific antigen: current status. , 2001, Folia biologica.
[108] E. Feuer,et al. Impact of screening on incidence and mortality of prostate cancer in the United States. , 2001, Epidemiologic reviews.
[109] F. Zattoni,et al. European Association of Urology GUIDELINES ON PROSTATE CANCER , 2001 .
[110] C. Baird,et al. The pilot study. , 2000, Orthopedic nursing.
[111] H. Federrath,et al. Design issues , 2008 .
[112] W. Isaacs,et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.
[113] M. Brawer,et al. Prostate‐specific antigen: Current status , 1999, CA: a cancer journal for clinicians.
[114] A W Partin,et al. Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.
[115] E. Feuer,et al. Asymptomatic incidence and duration of prostate cancer. , 1998, American journal of epidemiology.
[116] A S Whittemore,et al. Prostate cancer incidence and mortality in the United States and the United Kingdom. , 1998, Journal of the National Cancer Institute.
[117] A W Partin,et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.
[118] P. Walsh,et al. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. , 1997, The Journal of urology.
[119] D. Ornstein,et al. Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. , 1997, The Journal of urology.
[120] J. Oesterling,et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. , 1996, Urology.
[121] T. Stamey,et al. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. , 1996, The Journal of urology.
[122] C Parkes,et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer , 1995, BMJ.
[123] F C Lowe,et al. Prostatic acid phosphatase in 1993. Its limited clinical utility. , 1993, The Urologic clinics of North America.
[124] Dale McLerran,et al. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. , 1993, JAMA.
[125] D. Chan,et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. , 1992, Cancer research.
[126] O. Nilsson,et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.
[127] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[128] T. Stamey,et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.
[129] R L Vessella,et al. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. , 1987, The Journal of urology.
[130] I. Romslo. Prostatic acid phosphatase. , 1971, British medical journal.
[131] M. Uslenghi,et al. The World Space Observatory (WSO-UV) - Current status , 2008, 0801.2080.